Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1993 1
1995 1
2005 1
2007 1
2010 1
2015 1
2018 1
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Pancreatic Neuroendocrine Carcinoma"
Page 1
Everolimus.
Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. Recent Results Cancer Res. 2018. PMID: 30069763 Review.
Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduction pathway. The mTOR pathway regulates cell growth, proliferation and survival, and is frequently deregulated in cancer.The EMA has …
Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduct …
Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J, Vijayvergia N. Kaur J, et al. Curr Oncol. 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. Curr Oncol. 2023. PMID: 37754542 Free PMC article. Review.
Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas, and they can vary significantly in terms of clinical behavior and prognosis. ...Imm …
Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of rare tumors that arise from neuroendocri …
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Ikeda M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Kondo S, Morizane C, Ueno H, Okusaka T. Ikeda M, et al. J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):623-7. doi: 10.1002/jhbp.228. Epub 2015 Mar 5. J Hepatobiliary Pancreat Sci. 2015. PMID: 25755102 Review.
Pancreatic neuroendocrine carcinoma (P-NEC) resembles small cell lung carcinoma in its biologic and clinical features, such as rapid growth and relatively high sensitivity to platinum-based chemotherapy. And, etoposide plus cisplatin (EP) or iri …
Pancreatic neuroendocrine carcinoma (P-NEC) resembles small cell lung carcinoma in its biologic and clini …
Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.
Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, Sempoux C, Goffette P, Ciccarelli O, Borbath I, Hubert C, Gigot JF, Hassoun Z, Lerut J. Bonaccorsi-Riani E, et al. Transpl Int. 2010 Jul;23(7):668-78. doi: 10.1111/j.1432-2277.2010.01086.x. Epub 2010 May 5. Transpl Int. 2010. PMID: 20478000 Free article. Review.
Neuroendocrine tumor (NET) metastases represent at this moment the only accepted indication of liver transplantation (LT) for liver secondaries. ...Indications for LT were an invalidating unresectable tumor (4x), and/or a diffuse tumor localization (3x) and/or a refract …
Neuroendocrine tumor (NET) metastases represent at this moment the only accepted indication of liver transplantation (LT) for liver s …
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J. Okuyama H, et al. Neuroendocrinology. 2020;110(11-12):988-993. doi: 10.1159/000505550. Epub 2020 Jan 2. Neuroendocrinology. 2020. PMID: 31986515 Free article. Clinical Trial.
BACKGROUND: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established. OBJECTIVES: We evaluated the safety and efficacy of ever …
BACKGROUND: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine …
Islet cell tumors of the pancreas.
Bieligk S, Jaffe BM. Bieligk S, et al. Surg Clin North Am. 1995 Oct;75(5):1025-40. doi: 10.1016/s0039-6109(16)46744-7. Surg Clin North Am. 1995. PMID: 7660247 Review.
Pancreatic endocrine neoplasms are a heterogeneous group of tumors that produce active hormones and result in distinct clinical syndromes. ...With heightened awareness of these syndromes, increasing numbers of patients can be identified and more effective treatments develo …
Pancreatic endocrine neoplasms are a heterogeneous group of tumors that produce active hormones and result in distinct clinical syndr …
Radical resection combined with liver transplantation for foregut tumors.
Farmer DG, Shaked A, Colonna JO 2nd, Olthoff KM, Jurim O, Colquhoun S, Millis JM, Busuttil RW. Farmer DG, et al. Am Surg. 1993 Dec;59(12):806-12. Am Surg. 1993. PMID: 8256933 Review.
Between February 1984 and July 1992, six adults with advanced pancreatic adenocarcinoma (n = 1), pancreatic neuroendocrine tumor (n = 2), and cholangiocarcinoma (n = 3) underwent radical foregut resections (n = 3) or radical pancreaticoduodenectomy (n = 3) co …
Between February 1984 and July 1992, six adults with advanced pancreatic adenocarcinoma (n = 1), pancreatic neuroendocrine …
Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.
Banasch M, Schmitz F. Banasch M, et al. Wien Klin Wochenschr. 2007;119(19-20):573-8. doi: 10.1007/s00508-007-0884-2. Wien Klin Wochenschr. 2007. PMID: 17985090
The Zollinger-Ellison syndrome is characterized pathophysiologically by a significant hypergastrinemia derived from a gastrin-secreting neuroendocrine tumor with a primary location in the pancreas or duodenum. Chronic hypergastrinemia in turn triggers gastric acid hypersec …
The Zollinger-Ellison syndrome is characterized pathophysiologically by a significant hypergastrinemia derived from a gastrin-secreting n …
Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients.
Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Marinou K, Safioleas M, Karamanolis D. Nikou GC, et al. Hepatogastroenterology. 2005 Nov-Dec;52(66):1668-76. Hepatogastroenterology. 2005. PMID: 16334754
A variety of other gastrointestinal peptides, as well as the general neuroendocrine tumor marker, Chromogranin-A (CgA) were also estimated. ...RESULTS: At the time of presentation, 91% pts, had symptoms of peptic ulcer disease, refractory to treatment, while a histo …
A variety of other gastrointestinal peptides, as well as the general neuroendocrine tumor marker, Chromogranin-A (CgA) were also esti …
Amelioration of hypoglycemia in a patient with malignant insulinoma during the development of the ectopic ACTH syndrome.
Sadoff L, Gordon J, Goldman S. Sadoff L, et al. Diabetes. 1975 Jun;24(6):600-3. doi: 10.2337/diab.24.6.600. Diabetes. 1975. PMID: 237800
A patient with functioning islet cell carcinoma is described who had amelioration of her hypoglycemia during the development of ectopic ACTH syndrome. ...Prophylactic antituberculous therapy should be given to high-risk patients with the ectopic ACTH syndrome …
A patient with functioning islet cell carcinoma is described who had amelioration of her hypoglycemia during the develo …